

## Evonik Financials & ESG top KPIs

---

Financial KPIs Group	P. 2
ESG KPIs Group	P. 3
Division KPIs	P. 4-7
Group Income Statement	P. 8-9
Group Balance Sheet	P. 10
Group Cash Flow Statement	P. 11
Group Net Financial Position	P. 12
Definitions	P. 13

As of Q4 / FY 2024 (published March 5, 2025)

## Evonik Group Financials

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY
External Sales	12,199	14,955	18,488	4,005	3,886	3,771	3,604	15,267	3,796	3,930	3,832	3,599	15,157
Growth (%)	-7%	23%	24%	-11%	-19%	-23%	-17%	-17%	-5%	1%	2%	0%	-1%
Volumes (%)	-3%	11%	-4%	-14%	-9%	-5%	-2%	-8%	4%	5%	5%	4%	4%
Prices (%)	-3%	12%	18%	3%	-5%	-6%	-5%	-3%	-5%	-2%	0%	-2%	-2%
Exchange Rates (%)	-2%	-2%	5%	1%	-2%	-4%	-5%	-2%	-1%	0%	-2%	0%	-1%
Other (incl. M&A; %)	1%	2%	5%	-1%	-3%	-8%	-5%	-4%	-3%	-2%	-1%	-2%	-2%
Adjusted EBITDA	1,906	2,383	2,490	409	450	485	312	1,656	522	578	577	388	2,065
Margin (%)	15.6%	15.9%	13.5%	10.2%	11.6%	12.9%	8.7%	10.8%	13.8%	14.7%	15.1%	10.8%	13.6%
EBIT	819	1,173	942	83	-255	-101	30	-243	252	93	322	-91	577
Adjusted EBIT	890	1,338	1,350	130	157	202	32	521	266	329	322	111	1,027
Margin (%)	7.3%	8.9%	7.3%	3.2%	4.0%	5.4%	0.9%	3.4%	7.0%	8.4%	8.4%	3.1%	6.8%
Adjusted EPS	1.37	2.12	2.26	0.25	0.26	0.41	-0.12	0.79	0.42	0.50	0.58	0.16	1.67
Free Cash Flow	780	950	785	21	-203	469	515	801	127	217	357	172	873
Cash Conversion Rate <sup>1</sup>	41%	40%	32%					48%					42%
Capex (Cash outflow for investment in intangible assets, pp&e)	956	865	865	206	237	162	188	793	251	143	180	266	840
Capital employed (annual average)	14,600	14,799	16,192					15,406					14,493
ROCE (%)	6.1%	9.0%	8.3%					3.4%					7.1%
Dividend (€)	1.15	1.17	1.17					1.17					1.17
Employees (continuing operations)	33,106	33,004	34,029	33,918	33,357	33,575	33,409	33,409	33,090	32,757	32,040	31,930	31,930

<sup>1</sup> Free cash flow conversion = FCF / adj. EBITDA

## Evonik Group Environment, Social & Governance KPIs

Full set of ESG KPIs published separately on our IR website: [evonik.finance/investor-relations](https://evonik.finance/investor-relations)

	2020 FY	2021 FY	2022 FY	2023 FY	2024 FY
<b>Strategy &amp; Growth</b>					
Sales share with "Next Generation Solutions"	37%	41%	43%	43%	45%
<b>Governance &amp; Compliance</b>					
Training rate fighting money laundering	82%	96%	97%	98%	99%
Training rate antitrust law	88%	83%	85%	89%	90%
Training rate fighting corruption	88%	92%	91%	86%	95%
Training rate code of conduct	89%	89%	89%	92%	96%
Training rate Human Rights (new in 2024)				90%	84%
<b>Value Chain &amp; Products</b>					
Procurement volume (in € billion)	8.0	10.4	13.6	11.3	10.5
Production output (million metric tons)	8.9	9.5	8.4	7.5	7.3
Use of renewable raw materials in production	8.5%	9.7%	11.1%	12.0%	9.0%
Raw material suppliers covered by TfS assessments	73%	69%	66%	67%	71%
No. of sustainability audits (Evonik/TfS)	258	284	378	492	596
No. of sustainability assessments (Evonik/TfS)	1,148	1,345	1,545	1,296	1,309
R&D expenses (€ million)	433	464	461	443	459
<b>The environment</b>					
Scope 1 greenhouse gas emissions (thousands metric tons CO <sub>2</sub> )	4,860	4,381 <sup>a</sup>	4,221 <sup>a</sup>	3890 <sup>b</sup>	3,390
Scope 2 greenhouse gas emissions (thousands metric tons CO <sub>2</sub> )	571 <sup>b</sup>	1,916 <sup>a</sup>	1,757 <sup>a</sup>	1400 <sup>b</sup>	1,670
Scope 3 greenhouse gas emissions (million metric tons CO <sub>2</sub> )	20.0 <sup>b</sup>	23.4	20.5 <sup>a</sup>	18.9 <sup>b</sup>	21.6
% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO <sub>2</sub> ) vs base year	-43	-43	-5 <sup>c</sup>	-15 <sup>c</sup>	-20
Total water intake (in million m <sup>3</sup> )	561.4	462 <sup>d</sup>	444 <sup>d</sup>	403	431
Specific water intake (in m <sup>3</sup> freshwater / metric ton production)	36.5	26.8 <sup>d</sup>	29.5 <sup>d</sup>	29.9	32.2
Production waste (thousand metric tons)	311	342 <sup>d</sup>	335 <sup>d</sup>	287	306
Specific production waste (in ton of waster per metric ton production)		0.036	0.04	0.038	0.042
<b>Employees</b>					
Early employee turnover	1.3%	2.2%	1.9%	2.2%	1.7%
Continuing professional development per employee (hours)	12	5	4	4	2
Women at level "Executives" (circle 1)	15.9%	17.7%	20.3%	22.2%	21.8%
Women at level "Senior management" (circle 2)	14.2%	17.6%	17.1%	18.5%	19.1%
Women in management (circle 3)	27.1%	28.7%	29.9%	30.3%	31.4%
Women in management (circles 1-3)	26.1%	27.9%	29.1%	29.6%	30.7%
<b>Safety</b>					
Occupational health performance index	5.4	5.6	5.5	5.5	5.5
Accident frequency rate (no. of accidents / working hours) <sup>b</sup>	0.16	0.19	0.25	0.21	0.14
Incident frequency rate (no. of accidents / working hours) <sup>b</sup>	1.45	0.48	0.49	0.43	0.44

a: adjusted figures corresponding to GHG Protocol Standards | b: Correction of data based on methodological improvements | c: for new target period 2021-2030 | d: data corrected for fast-close process

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY
Sales	3,225	3,710	4,184	921	906	882	811	3,520	908	944	897	828	3,578
<i>Growth (%)</i>	-5%	15%	13%	-12%	-19%	-21%	-11%	-16%	-1%	4%	2%	2%	2%
<i>Volumes (%)</i>	-3%	11%	-8%	-15%	-15%	-11%	0%	-11%	5%	11%	8%	5%	7%
<i>Prices (%)</i>	0%	5%	16%	5%	1%	-3%	-5%	0%	-5%	-6%	-4%	-3%	-5%
<i>Exchange Rates (%)</i>	-2%	-1%	4%	0%	-2%	-5%	-4%	-3%	-1%	-1%	-2%	0%	0%
<i>Other (incl. M&amp;A; %)</i>	0%	0%	1%	-2%	-3%	-2%	-2%	-2%	0%	0%	0%	0%	0%
Adjusted EBITDA	857	920	946	168	199	173	134	673	185	220	208	131	744
<i>Margin (%)</i>	26.6%	24.8%	22.6%	18.2%	22.0%	19.6%	16.5%	19.1%	20.4%	23.3%	23.2%	15.8%	20.8%
EBIT	683	739	782	117	150	127	87	481	139	175	164	84	562
Adjusted EBIT	681	739	753	121	152	127	88	489	139	175	164	84	562
<i>Margin (%)</i>	21.1%	19.9%	18.0%	13.1%	16.8%	14.4%	10.9%	13.9%	15.3%	18.5%	18.3%	10.1%	15.7%
Capital expenditures	93	94	106	26	28	29	41	124	23	24	25	39	111
Capital employed (annual average)	4,244	4,168	4,631					4,403					4,185
ROCE (%)	16.0%	17.7%	16.3%					11.1%					13.4%
Employees	3,666	3,693	3,824	3,556	3,545	3,538	3,492	3,492	3,451	3,409	3,411	3,391	3,391

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY
Sales	2,992	3,557	4,237	886	893	924	908	3,611	900	905	996	962	3,764
<i>Growth (%)</i>	2%	19%	19%	-15%	-13%	-13%	-18%	-15%	2%	1%	8%	6%	4%
<i>Volumes (%)</i>	2%	10%	-4%	-12%	3%	5%	-9%	-3%	2%	-5%	3%	3%	1%
<i>Prices (%)</i>	4%	11%	16%	-2%	-11%	-10%	0%	-6%	1%	5%	10%	3%	4%
<i>Exchange Rates (%)</i>	-4%	-2%	7%	0%	-3%	-7%	-9%	-5%	-1%	1%	-5%	0%	-1%
<i>Other (incl. M&amp;A; %)</i>	0%	0%	0%	-1%	-2%	-1%	0%	-1%	0%	0%	0%	0%	0%
Sales Animal Nutrition	1,474	1,789	2,192	441	437	447	425	1,750	483	450	512	489	1,934
Sales Health & Care	1,518	1,768	2,045	445	457	477	483	1,861	417	455	484	473	1,829
Adjusted EBITDA	560	717	677	76	71	127	115	389	140	140	194	126	601
<i>Margin (%)</i>	18.7%	20.2%	16.0%	8.6%	8.0%	13.7%	12.7%	10.8%	15.6%	15.5%	19.5%	13.1%	16.0%
EBIT	285	404	396	17	-298	58	54	-170	87	87	174	-35	313
Adjusted EBIT	301	453	405	13	7	69	59	147	88	87	140	62	377
<i>Margin (%)</i>	10.1%	12.7%	9.6%	1.5%	0.8%	7.5%	6.5%	4.1%	9.8%	9.6%	14.1%	6.4%	10.0%
Capital expenditures	139	164	243	59	106	79	67	311	66	46	60	111	283
Capital employed (annual average)	3,914	3,893	4,286					3,970					3,860
ROCE (%)	7.7%	11.6%	9.4%					3.7%					9.8%
Employees	5,295	5,453	5,690	5,745	5,807	5,697	5,630	5,630	5,560	5,535	5,542	5,514	5,514

in € million	2020 FY	2021 FY	2022 FY <sup>1</sup>	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY
Sales	3,235	3,918	5,240	1,188	1,119	1,100	1,054	4,461	1,093	1,147	1,098	1,112	4,450
<i>Growth (%)</i>	-4%	21%	23%	-7%	-16%	-19%	-16%	-15%	-8%	3%	0%	6%	0%
<i>Volumes (%)</i>	-7%	16%	1%	-16%	-17%	-12%	-7%	-13%	0%	7%	2%	5%	3%
<i>Prices (%)</i>	-1%	4%	18%	10%	3%	-4%	-7%	0%	-8%	-4%	0%	-1%	-3%
<i>Exchange Rates (%)</i>	-2%	-2%	4%	0%	-2%	-3%	-3%	-2%	-1%	0%	-2%	0%	-1%
<i>Other (incl. M&amp;A; %)</i>	6%	3%	0%	-1%	0%	0%	1%	0%	1%	0%	0%	2%	1%
Sales Inorganics	2,315	2,754	3,891	860	820	793	765	3,238	790	827	795	806	3,218
Sales Polymers	920	1,164	1,349	328	299	307	290	1,224	302	320	303	307	1,232
Adjusted EBITDA	529	650	743	164	122	135	119	540	159	171	164	106	601
<i>Margin (%)</i>	16.4%	16.6%	14.2%	13.8%	10.9%	12.3%	11.3%	12.1%	14.5%	14.9%	14.9%	9.5%	13.5%
EBIT	226	346	405	71	-51	-9	46	57	73	91	81	-68	177
Adjusted EBIT	270	374	416	79	34	41	27	181	75	92	82	18	268
<i>Margin (%)</i>	8.3%	9.5%	7.9%	6.6%	3.0%	3.7%	2.6%	4.1%	6.9%	8.0%	7.5%	1.6%	6.0%
Capital expenditures	466	379	266	46	51	50	89	236	49	47	55	89	240
Capital employed (annual average)	4,244	4,637	5,109					5,010					4,869
ROCE (%)	6.4%	8.1%	8.1%					3.6%					5.5%
Employees	7,874	7,742	8,011	8,095	8,113	8,079	8,103	8,103	8,126	8,054	8,023	7,942	7,942

<sup>1</sup> Restated for the alkoxides business (€407 m in sales and €59 m in adj. EBITDA in FY 2022), which was moved from Performance Materials to Smart Materials as of January 1st, 2023; sales growth rates and price/volume analysis not restated

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3 <sup>1</sup>	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3 <sup>2</sup>	2024 Q4	2024 FY
Sales	2,747	3,771	4,827	1,010	968	865	832	3,675	895	934	841	695	3,365
<i>Growth (%)</i>	-20%	37%	28%	-10%	-25%	-35%	-22%	-24%	-11%	-4%	-3%	-16%	-8%
Adjusted EBITDA	-40	96	124	1	58	50	-54	54	38	47	11	23	119
EBIT	-375	-316	-641	-122	-56	-277	-156	-611	-47	-260	-97	-71	-475
Adjusted EBIT	-362	-228	-224	-83	-36	-35	-142	-296	-36	-25	-64	-55	-180
Capital expenditures	297	292	241	50	42	39	58	189	34	33	40	75	182
Employees	16,271	16,116	16,504	16,522	15,892	16,261	16,184	16,184	15,953	15,759	15,064	15,083	15,083

1. Excluding divested Lülldorf site from Q3 2023 onwards (sales of €650 m in FY 2022)

2. Excluding divested Superabsorber business from Q3 2024 onwards (sales of €892 m in FY 2023)

For historical figures of the former Performance Materials division alone, see "Evonik Financials" from Q3 2024 (or earlier) on our IR website: [evonik.finance/investor-relations](https://evonik.finance/investor-relations)

## Group Income Statement

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY
Sales	12,199	14,955	18,488	4,005	3,886	3,771	3,604	15,267	3,796	3,930	3,832	3,599	15,157
Cost of sales	-8,865	-10,925	-14,257	-3,143	-3,392	-3,181	-2,850	-12,567	-2,795	-2,885	-2,804	-2,935	-11,419
<b>Gross profit on sales</b>	<b>3,334</b>	<b>4,030</b>	<b>4,231</b>	<b>862</b>	<b>494</b>	<b>590</b>	<b>754</b>	<b>2,700</b>	<b>1,001</b>	<b>1,045</b>	<b>1,028</b>	<b>664</b>	<b>3,738</b>
Selling expenses	-1,501	-1,717	-2,035	-483	-471	-438	-443	-1,836	-473	-473	-468	-479	-1,894
Research and development expenses	-433	-464	-460	-113	-107	-115	-108	-443	-111	-109	-106	-133	-459
General administrative expenses	-531	-546	-554	-133	-125	-113	-117	-488	-129	-353	-128	-129	-740
Other operating income & expenses	-65	-138	-252	-52	-49	-26	-59	-186	-38	-22	-7	-24	-89
Result from investments recognized at equity	15	8	12	2	3	1	3	10	2	5	3	10	21
<b>Income before financial result and income taxes, cont. ops. = EBIT</b>	<b>819</b>	<b>1,173</b>	<b>942</b>	<b>83</b>	<b>-255</b>	<b>-101</b>	<b>30</b>	<b>-243</b>	<b>252</b>	<b>93</b>	<b>322</b>	<b>-91</b>	<b>577</b>
Financial Result	-135	-88	-19	-14	-30	-13	-50	-108	-33	-31	-48	-30	-143
<b>Income before income taxes, continuing operations</b>	<b>684</b>	<b>1,085</b>	<b>923</b>	<b>69</b>	<b>-285</b>	<b>-114</b>	<b>-20</b>	<b>-351</b>	<b>219</b>	<b>62</b>	<b>274</b>	<b>-121</b>	<b>434</b>
Income taxes	-181	-316	-369	-20	19	23	-124	-101	-59	-61	-47	-28	-194
<b>Income after taxes, continuing operations</b>	<b>503</b>	<b>769</b>	<b>554</b>	<b>49</b>	<b>-266</b>	<b>-91</b>	<b>-144</b>	<b>-452</b>	<b>160</b>	<b>1</b>	<b>227</b>	<b>-149</b>	<b>240</b>
Income after taxes, discontinued operations	-24	-2	1	-	-	-	-	-	0	0	0	1	0
<b>Income after taxes</b>	<b>479</b>	<b>767</b>	<b>555</b>	<b>49</b>	<b>-266</b>	<b>-91</b>	<b>-144</b>	<b>-452</b>	<b>160</b>	<b>1</b>	<b>227</b>	<b>-148</b>	<b>240</b>
thereof attributable to non-controlling interests	14	21	15	2	4	5	2	13	4	6	4	4	18
<b>Shareholders of EVONIK Industries AG (net income)</b>	<b>465</b>	<b>746</b>	<b>540</b>	<b>47</b>	<b>-270</b>	<b>-96</b>	<b>-146</b>	<b>-465</b>	<b>156</b>	<b>-5</b>	<b>223</b>	<b>-152</b>	<b>222</b>
<b>EPS</b>	<b>1.00</b>	<b>1.60</b>	<b>1.16</b>	<b>0.10</b>	<b>-0.58</b>	<b>-0.21</b>	<b>-0.31</b>	<b>-1.00</b>	<b>0.33</b>	<b>-0.01</b>	<b>0.48</b>	<b>-0.32</b>	<b>0.48</b>

## Group Adjusted Income Statement

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY
<b>Sales</b>	<b>12,199</b>	<b>14,955</b>	<b>18,488</b>	<b>4,005</b>	<b>3,886</b>	<b>3,771</b>	<b>3,604</b>	<b>15,267</b>	<b>3,796</b>	<b>3,930</b>	<b>3,832</b>	<b>3,599</b>	<b>15,157</b>
<b>Adjusted EBITDA</b>	<b>1,906</b>	<b>2,383</b>	<b>2,490</b>	<b>409</b>	<b>450</b>	<b>485</b>	<b>312</b>	<b>1,656</b>	<b>522</b>	<b>578</b>	<b>577</b>	<b>388</b>	<b>2,065</b>
Adjusted depreciation and amortization	-1,016	-1,045	-1,140	-279	-293	-283	-280	-1,135	-256	-249	-255	-278	-1,038
<b>Adjusted EBIT</b>	<b>890</b>	<b>1,338</b>	<b>1,350</b>	<b>130</b>	<b>157</b>	<b>202</b>	<b>32</b>	<b>521</b>	<b>266</b>	<b>329</b>	<b>322</b>	<b>110</b>	<b>1,027</b>
Adjusted net financial result	-146	-97	-19	-12	-27	-13	-50	-103	-33	-31	-48	-31	-143
Adjusted depreciation and amortization on intangible assets	149	162	169	41	39	38	35	153	35	35	34	40	144
<b>Adjusted income before income taxes, cont. ops.</b>	<b>893</b>	<b>1,403</b>	<b>1,500</b>	<b>159</b>	<b>169</b>	<b>227</b>	<b>17</b>	<b>571</b>	<b>268</b>	<b>333</b>	<b>308</b>	<b>119</b>	<b>1,028</b>
Adjusted income taxes, continuing operations	-239	-396	-431	-42	-42	-33	-71	-188	-67	-93	-33	-40	-233
<b>Adjusted income after taxes</b>	<b>654</b>	<b>1,007</b>	<b>1,069</b>	<b>117</b>	<b>127</b>	<b>194</b>	<b>-54</b>	<b>383</b>	<b>201</b>	<b>240</b>	<b>275</b>	<b>79</b>	<b>795</b>
Adjusted non-controlling interest	-14	-21	-15	-2	-4	-5	-2	-13	-4	-6	-4	-4	-18
<b>Adjusted net income</b>	<b>640</b>	<b>986</b>	<b>1,054</b>	<b>115</b>	<b>123</b>	<b>189</b>	<b>-56</b>	<b>370</b>	<b>197</b>	<b>234</b>	<b>271</b>	<b>74</b>	<b>777</b>
<b>Adjusted EPS</b>	<b>1.37</b>	<b>2.12</b>	<b>2.26</b>	<b>0.25</b>	<b>0.26</b>	<b>0.41</b>	<b>-0.12</b>	<b>0.79</b>	<b>0.42</b>	<b>0.50</b>	<b>0.58</b>	<b>0.16</b>	<b>1.67</b>

## Adjustments

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY
Restructuring measures	-31	-32	-121	-35	-10	-13	-6	-64	-2	-228	-2	-173	-405
Acquisitions and divestments	-40	-29	40	-7	-7	-235	13	-237	-11	-2	-18	-3	-34
Other special items	0	-104	-327	-5	-395	-55	-9	-463	-1	-6	20	-24	-11
= Adjustments	-71	-165	-408	-47	-412	-303	-2	-764	-14	-236	0	-200	-450

Adjustment categories changed as of December 31, 2023 to avoid overlaps between categories; prior year figures restated

## Group Balance Sheet

### Assets

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY
Intangible assets	5,877	6,045	5,710	5,613	5,585	5,609	5,525	5,556	5,552	5,417	5,571
Property, plant and equipment	6,588	6,963	6,962	6,893	6,269	6,276	6,294	6,320	6,307	6,270	6,450
Right of use assets (capitalized leasing)	668	608	972	967	974	984	965	940	928	903	947
Investments recognized at equity	75	81	88	89	82	82	52	44	40	43	49
Financial assets	607	581	441	319	385	425	460	445	444	509	467
Deferred tax assets	2,004	1,755	890	1,001	1,100	991	642	672	678	677	664
Other income tax assets	13	16	19	20	20	21	20	21	22	21	25
Other non-financial assets	102	125	64	61	69	74	78	77	58	59	69
<b>Non-current assets</b>	<b>15,934</b>	<b>16,174</b>	<b>15,146</b>	<b>14,963</b>	<b>14,484</b>	<b>14,462</b>	<b>14,036</b>	<b>14,075</b>	<b>14,029</b>	<b>13,899</b>	<b>14,242</b>
Inventories	1,806	2,548	2,820	3,093	2,919	2,716	2,349		2,599	2,658	2,662
Other income tax assets	211	199	98	98	102	140	209	189	179	122	166
Trade accounts receivable	1,455	1,954	1,898	2,046	1,848	1,802	1,607		1,813	1,706	1,622
Other non-financial assets	231	382	517	582	622	535	373	407	462	433	381
Financial assets	697	571	610	530	437	291	381	371	342	284	216
Cash and cash equivalents	563	456	645	634	398	588	749	794	521	460	461
<b>Current assets</b>	<b>4,963</b>	<b>6,110</b>	<b>6,588</b>	<b>6,983</b>	<b>6,326</b>	<b>6,072</b>	<b>5,668</b>	<b>6,109</b>	<b>5,916</b>	<b>5,663</b>	<b>5,508</b>
Assets held for sale	0	0	76	64	486	262	236	264	261	0	0
<b>Current assets</b>	<b>4,963</b>	<b>6,110</b>	<b>6,664</b>	<b>7,047</b>	<b>6,812</b>	<b>6,334</b>	<b>5,904</b>	<b>6,373</b>	<b>6,177</b>	<b>5,663</b>	<b>5,508</b>
<b>Total assets</b>	<b>20,897</b>	<b>22,284</b>	<b>21,810</b>	<b>22,010</b>	<b>21,296</b>	<b>20,796</b>	<b>19,940</b>	<b>20,448</b>	<b>20,206</b>	<b>19,562</b>	<b>19,750</b>

### Liabilities

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY
Issued capital	466	466	466	466	466	466	466	466	466	466	466
Reserves	7,546	8,823	10,508	10,265	9,317	9,653	8,444	8,672	8,401	8,552	8,554
<b>Equity attributable to shareholders of Evonik Industries AG</b>	<b>8,012</b>	<b>9,289</b>	<b>10,974</b>	<b>10,731</b>	<b>9,783</b>	<b>10,119</b>	<b>8,910</b>	<b>9,138</b>	<b>8,867</b>	<b>9,018</b>	<b>9,020</b>
Equity attributable to non-controlling interests	87	83	82	81	78	79	76	78	71	77	80
<b>Total equity</b>	<b>8,099</b>	<b>9,372</b>	<b>11,056</b>	<b>10,812</b>	<b>9,861</b>	<b>10,198</b>	<b>8,986</b>	<b>9,216</b>	<b>8,938</b>	<b>9,095</b>	<b>9,100</b>
Provisions for pensions and other post-employment benefits	4,618	3,766	1,359	1,547	1,624	1,189	1,858	1,828	1,575	1,564	1,662
Other provisions	715	657	542	526	513	508	517	520	688	681	734
Deferred tax liabilities	586	628	661	649	635	653	608	613	630	614	638
Other income tax liabilities	275	195	246	251	250	249	268	273	271	266	254
Financial liabilities	3,564	3,531	4,117	4,112	4,279	3,483	3,502	3,519	3,485	3,135	3,162
Other payables	114	143	182	138	147	146	153	139	129	130	141
<b>Non-current liabilities</b>	<b>9,872</b>	<b>8,920</b>	<b>7,107</b>	<b>7,223</b>	<b>7,448</b>	<b>6,228</b>	<b>6,906</b>	<b>6,892</b>	<b>6,778</b>	<b>6,390</b>	<b>6,591</b>
Other provisions	744	892	732	818	546	569	606	681	711	833	923
Other income tax liabilities	136	211	189	180	172	164	124	152	151	111	87
Financial liabilities	434	477	429	346	795	1,330	1,153	1,130	1,205	1,083	1,034
Trade accounts payable	1,273	2,022	1,735	1,925	1,659	1,531	1,521	1,675	1,682	1,511	1,600
Other payables	339	390	501	640	630	585	457	485	535	539	415
<b>Current liabilities</b>	<b>2,926</b>	<b>3,992</b>	<b>3,586</b>	<b>3,909</b>	<b>3,802</b>	<b>4,179</b>	<b>3,861</b>	<b>4,123</b>	<b>4,284</b>	<b>4,077</b>	<b>4,059</b>
Liabilities associated with assets held for sale	0	0	61	66	185	191	187	217	206	0	0
<b>Current liabilities</b>	<b>2,926</b>	<b>3,992</b>	<b>3,647</b>	<b>3,975</b>	<b>3,987</b>	<b>4,370</b>	<b>4,048</b>	<b>4,340</b>	<b>4,490</b>	<b>4,077</b>	<b>4,059</b>
<b>Total equity and liabilities</b>	<b>20,897</b>	<b>22,284</b>	<b>21,810</b>	<b>22,010</b>	<b>21,296</b>	<b>20,796</b>	<b>19,940</b>	<b>20,448</b>	<b>20,206</b>	<b>19,562</b>	<b>19,750</b>

## Group Cash Flow Statement

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY
Income before financial result and income taxes, continuing operations = EBIT	819	1,173	942	83	-255	-101	30	-243	252	93	321	-90	577
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	1,018	1,073	1,568	311	675	574	281	1,841	265	250	234	368	1,117
Result from investments recognized at equity	-15	-8	-12	-2	-4	-1	-3	-10	-2	-6	-3	-10	-21
Gains/losses on disposal of non current assets	-10	43	-50	-1	13	0	-13	-1	-3	-1	21	5	22
Change in inventories	70	-675	-270	-300	52	227	331	310	-218	-34	-99	54	-297
Change in trade accounts receivable	54	-449	42	-178	50	61	172	105	-180	-35	118	118	21
Change in trade accounts payable and current advance payments received from customers	-30	680	-257	223	-127	-177	-76	-157	261	-11	-180	4	74
Change in provisions for pensions and other post-employment benefits	-14	83	-19	-5	-15	-31	-4	-55	-31	-13	0	-4	-48
Change in other provisions	-133	207	-149	92	-263	31	-1	-141	76	192	126	141	535
Change in miscellaneous assets/liabilities	33	-23	10	53	-46	108	38	152	-28	-23	16	-45	-81
Cash inflows from dividends	27	19	19	11	5	0	9	25	-	20	1	6	27
Tax payments relating to carve-out of the methacrylates business	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash inflows/outflows for income taxes	-83	-308	-174	-60	-51	-60	-61	-232	-14	-72	-18	-109	-213
<b>Cash flow from operating activities, continuing operations</b>	<b>1,736</b>	<b>1,815</b>	<b>1,650</b>	<b>227</b>	<b>34</b>	<b>631</b>	<b>703</b>	<b>1,594</b>	<b>378</b>	<b>360</b>	<b>537</b>	<b>438</b>	<b>1,713</b>
Cash flow from operating activities, discontinued operations	-9	0	0	0	0	0	0	0	0	0	0	0	0
<b>Cash flow from operating activities</b>	<b>1,727</b>	<b>1,815</b>	<b>1,650</b>	<b>227</b>	<b>34</b>	<b>631</b>	<b>703</b>	<b>1,594</b>	<b>378</b>	<b>360</b>	<b>537</b>	<b>438</b>	<b>1,713</b>
Cash outflows for investments in intangible assets, property, plant and equipment, investment property	-956	-865	-865	-206	-237	-162	-188	-793	-251	-143	-180	-266	-840
Cash outflows for investments in shareholdings	-474	-85	-27	-2	-35	-12	-46	-76	-3	-4	-14	0	-15
Cash outflows for loss from divestments of shareholdings	-	-145	97	-4	-22	-1	-14	-32	-13	0	0	0	-13
Cash outflows from divestments of businesses and other shareholdings	-	-21	-	-	-13	-	-	-5	-	0	0	0	-6
Cash inflows from divestments of intangible assets, property, plant and equipment, investment property	45	9	5	13	1	0	1	15	16	3	-5	7	21
Cash inflows for loss from divestments of shareholdings	65	2	-	43	0	2	-	43	-	3	17	-4	16
Cash inflows for investments in shareholdings	-	-	-	-	-	-	-	2	-	-	-	0	0
Cash inflows/outflows relating to securities, deposits and loans	720	23	-3	-21	120	149	-87	161	-13	14	85	52	137
Cash inflows from interest	30	12	16	10	10	6	6	32	12	8	11	6	37
<b>Cash flow from investing activities, continuing operations</b>	<b>-570</b>	<b>-1,070</b>	<b>-777</b>	<b>-167</b>	<b>-141</b>	<b>-17</b>	<b>-328</b>	<b>-653</b>	<b>-252</b>	<b>-119</b>	<b>-86</b>	<b>-205</b>	<b>-663</b>
Cash flow from investing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Cash flow from investing activities</b>	<b>-570</b>	<b>-1,070</b>	<b>-777</b>	<b>-167</b>	<b>-141</b>	<b>-17</b>	<b>-328</b>	<b>-653</b>	<b>-252</b>	<b>-119</b>	<b>-86</b>	<b>-205</b>	<b>-663</b>
Cash inflows/outflows relating to capital contributions	2	0	0	0	0	0	0	0	0	0	0	0	0
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-536	-545	0	-545	0	0	-545	0	-545	0	0	-545
Cash outflows for dividends to non-controlling interests	-16	-21	-13	-1	-3	-3	-3	-10	-4	-12	0	-4	-20
Cash inflows/outflows from changes in ownership interests in subsidiaries without loss of control	0	0	-5	0	0	0	0	-	-	0	0	-	0
Cash outflows for the purchase of treasury shares	-16	-15	-16	-16	0	0	-	-16	-12	0	0	0	-12
Cash inflows from the sale of treasury shares	12	12	12	0	12	-	-	12	-	9	0	0	9
Cash inflows from the addition of financial liabilities	1,039	655	1,649	54	490	151	21	716	19	134	487	68	708
Cash outflows for repayment of financial liabilities	-2,156	-948	-1,577	-93	-56	-529	-215	-893	-82	-65	-946	-261	-1,354
Cash inflows/outflows in connection with financial transactions	14	91	-104	3	7	6	-4	12	11	-16	7	-8	-7
Cash outflows for interest	-77	-94	-73	-15	-17	-51	-16	-99	-17	-15	-52	-25	-109
<b>Cash flow from financing activities, continuing operations</b>	<b>-1,734</b>	<b>-856</b>	<b>-672</b>	<b>-68</b>	<b>-112</b>	<b>-426</b>	<b>-217</b>	<b>-823</b>	<b>-85</b>	<b>-510</b>	<b>-504</b>	<b>-230</b>	<b>-1,330</b>
Cash flow from financing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Cash flow from financing activities</b>	<b>-1,734</b>	<b>-856</b>	<b>-672</b>	<b>-68</b>	<b>-112</b>	<b>-426</b>	<b>-217</b>	<b>-823</b>	<b>-85</b>	<b>-510</b>	<b>-504</b>	<b>-230</b>	<b>-1,330</b>
<b>Change in cash and cash equivalents</b>	<b>-577</b>	<b>-111</b>	<b>201</b>	<b>-8</b>	<b>-219</b>	<b>188</b>	<b>158</b>	<b>118</b>	<b>41</b>	<b>-269</b>	<b>-53</b>	<b>1</b>	<b>-280</b>
<b>Cash and cash equivalents as of beginning of period</b>	<b>1,165</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>633</b>	<b>398</b>	<b>589</b>	<b>645</b>	<b>749</b>	<b>794</b>	<b>519</b>	<b>460</b>	<b>749</b>
Change in cash and cash equivalents	-577	-111	201	-8	-219	188	158	118	41	-269	-53	3	-280
Changes in exchange rates and other changes in cash and cash equivalents	-25	4	-12	-3	-16	3	2	-14	4	-4	-7	-2	-8
<b>Cash and cash equivalents as of end of period</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>634</b>	<b>398</b>	<b>589</b>	<b>749</b>	<b>749</b>	<b>794</b>	<b>521</b>	<b>459</b>	<b>461</b>	<b>461</b>
Cash and cash equivalents included in assets held for sale	0	0	0	0	0	1	0	0	0	0	0	0	0
<b>Cash and cash equivalents as on the balance sheet as of end of period</b>	<b>563</b>	<b>456</b>	<b>645</b>	<b>634</b>	<b>398</b>	<b>588</b>	<b>749</b>	<b>749</b>	<b>794</b>	<b>521</b>	<b>459</b>	<b>461</b>	<b>461</b>

## Group Net Financial Position

in € million	2020 FY	2021 FY	2022 FY	2023 Q1	2023 Q2	2023 Q3	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY
Non-current financial liabilities	-3,564	-3,527	-4,074	-4,064	-4,118	-3,335	-3,320	-3,302	-3,288	-2,955	-2,961
Current financial liabilities	-368	-232	-243	-264	-711	-1,160	-1,006	-979	-1,105	-971	-883
<b>Financial debt</b>	<b>-3,932</b>	<b>-3,759</b>	<b>-4,317</b>	<b>-4,328</b>	<b>-4,829</b>	<b>-4,495</b>	<b>-4,326</b>	<b>-4,281</b>	<b>-4,393</b>	<b>-3,926</b>	<b>-3,844</b>
- Cash and cash equivalents	563	456	645	634	398	588	749	794	521	460	461
- Current securities	466	446	413	434	313	165	261	269	259	176	128
- Other financial assets	17	0	2	2	2	2	6	6	2	4	2
<b>Financial assets</b>	<b>1,046</b>	<b>902</b>	<b>1,060</b>	<b>1,070</b>	<b>713</b>	<b>755</b>	<b>1,016</b>	<b>1,069</b>	<b>782</b>	<b>640</b>	<b>591</b>
<b>Net financial debt/cash as stated on the balance sheet</b>	<b>-2,886</b>	<b>-2,857</b>	<b>-3,257</b>	<b>-3,258</b>	<b>-4,116</b>	<b>-3,740</b>	<b>-3,310</b>	<b>-3,212</b>	<b>-3,611</b>	<b>-3,286</b>	<b>-3,253</b>
<b>Net financial debt/cash, discontinued operations</b>	-	-	-	-	-	-	-	-	0	0	0
<b>Net financial debt/cash including discontinued operations</b>	<b>-2,886</b>	<b>-2,857</b>	<b>-3,257</b>	<b>-3,258</b>	<b>-4,116</b>	<b>-3,740</b>	<b>-3,310</b>	<b>-3,212</b>	<b>-3,611</b>	<b>-3,286</b>	<b>-3,253</b>

## Financial KPI Definitions

<b>Adjusted EBIT</b>	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
<b>Adjusted EBITDA</b>	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
<b>Adjusted net income</b>	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
<b>Adjustments</b>	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
<b>Free Cash Flow</b>	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
<b>ROCE</b>	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

## ESG KPI Definitions

<b>Value added in € million</b>	We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.
<b>Sales share with "Next Generation Solutions"</b>	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
<b>Internal Investigations</b>	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
<b>Disciplinary Measures</b>	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
<b>Raw Material Suppliers Covered by TFS Assessments</b>	This number indicates how many raw material suppliers have been covered by TFS assessments in that year. The chemical industry set up the Together for Sustainability (TFS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
<b>Greenhouse Gas Emissions</b>	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, energy requirements for offices and emissions from the disposal and recycling of products sold.
<b>Early Employee Turnover</b>	Turnover of newly hired employees within the first year of employment
<b>Management circles/ levels</b>	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
<b>Occupational Health Performance Index</b>	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.
<b>Specific water intake</b> <small>in m<sup>3</sup> freshwater per metric ton production</small>	Freshwater usage in relation to production.
<b>Total water intake</b>	Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water).